Escherichia coli uropatogeni

Prevalenza di

Escherichia coli uropatogeni

multiresistenti

isolati da cane e uomo

INTRODUZIONE

/HLQIH]LRQLGHOWUDWWRXULQDULR87,VRQRPROWRIUH

TXHQWL QHO FDQH H QHOO·XRPR 7UD JOL DJHQWL H]LRORJL

ci Escherichia coli q XQR GHL EDWWHUL SL FRPXQHPHQWH

FRLQYROWLQHOOHIRUPHFOLQLFKHGLFLVWLWH5LVXOWDLQIDWWL

O·DJHQWH FDXVDOH GHO  GHOOH 87, FKH FROSLVFR

QRO·XRPRHÀQRDOGHOOHLQIH]LRQLFDQLQH

. Il WUDWWDPHQWRGLTXHVWHSDWRORJLHSXzULVXOWDUHGLIÀFLOHD

FDXVDGHOODFDSDFLWjGHOPLFURUJDQLVPRGLFRORQL]]DUH

ODPXFRVDYHVFLFDOHGHOODSUHVHQ]DGLSDUWLFRODULIDWWRUL

GLYLUXOHQ]DHGHOIHQRPHQRGHOO·DQWLELRWLFRUHVLVWHQ]D

7DOL IDWWRUL GL ULVFKLR FRQWULEXLVFRQR DOO·LQVWDXUDUVL GL

IRUPHULFRUUHQWLFRQHYLGHQWLULSHUFXVVLRQLVXOO·HVLWRH

sui costi della terapia

,QROWUHQHJOLXOWLPLDQQLVLqDV

VLVWLWRDGXQDXPHQWRGHOODGLIIXVLRQHGHOO·DQWLELRWLFR

UHVLVWHQ]DVLDLQPHGLFLQDXPDQDFKHYHWHULQDULD

. Alcu

QLVWXGLHYLGHQ]LDQRO·HVLVWHQ]DGLXQDFRUUHOD]LRQHWUD

XVRGLDQWLPLFURELFLHOLYHOORGLDQWLELRWLFRUHVLVWHQ]D

SRQHQGR LQROWUH O·DWWHQ]LRQH VXO UXROR GHJOL DQLPDOL

GDFRPSDJQLDFRPHVHUEDWRLRGLEDWWHULUHVLVWHQWLSHU

l’uomo

3HUTXHVWRPRWLYRO·XVRSUXGHQWHGHJOLDQWL

ELRWLFLLQFDPSRXPDQRHYHWHULQDULRUDSSUHVHQWDXQD

SULRULWjSHUODVDOXWHSXEEOLFDVLDDOLYHOORQD]LRQDOHFKH

europeo.

,Q,WDOLDLGDWLULJXDUGDQWLLOOLYHOORGLDQWLELRWLFRUHVL

VWHQ]DQHOOHFLVWLWLFKHFROSLVFRQRJOLDQLPDOLGDFRPSD

JQLDVRQROLPLWDWLDSRFKLODYRUL

$EELDPRTXLQGL

ULWHQXWRLQWHUHVVDQWHDQDOL]]DUHODSUHYDOHQ]DGLFHSSL

XURSDWRJHQLPXOWLUHVLVWHQWLGLE. coli isolati da urine di FDQL FRQ FLVWLWH H FRQIURQWDUH L ULVXOWDWL RWWHQXWL FRQ

campioni di E. coliLVRODWLGDDQDORJKHLQIH]LRQLXULQDULH

nell’uomo.

MATERIALI E METODI

&HSSLEDWWHULFL

ËVWDWRHVHJXLWRXQRVWXGLRUHWURVSHWWLYRUHODWLYDPHQWH

DO SHULRGR FRPSUHVR WUD 0DU]R  H 0DU]R 

6RQRVWDWLSUHVLLQFRQVLGHUD]LRQHFHSSLGLE. coli di RULJLQHFDQLQDHGLRULJLQHXPDQD,FHSSLVRQRVWDWL

LVRODWLGDFDPSLRQLGLXULQDRWWHQXWLLQHQWUDPELLFDVL

GDSD]LHQWLFRQGLDJQRVLFOLQLFDGLFLVWLWHQRQFRPSOLFD

WD6LDSHUTXDQWRULJXDUGDO·XRPRFKHLOFDQHLFDPSLR

QLVRQRVWDWLUDFFROWLGDVRJJHWWLUHVLGHQWLLQ3LHPRQWH

7HVWGLVHQVLELOLWjDJOLDQWLPLFURELFL

3HUO·LGHQWLÀFD]LRQHGHOODVSHFLHEDWWHULFDHLWHVW

GLVHQVLELOLWjDJOLDQWLELRWLFLHIIHWWXDWLPHGLDQWH

FDOFROR GHOOD FRQFHQWUD]LRQH PLQLPD LQLEHQWH

Un problema emergente riguardo al trattamento delle infezioni urinarie sostenute da E. coli è rappresentato dalla diffusione di ceppi multiresistenti (MDR).

°
TUBUP
QFSUBOUP
DPOEPUUP
VOP
TUVEJP
SFUSPTQFUUJWP
QFS
WBMVUBSF
MB
SFTJTUFO[B

di ceppi di E. coli isolati dall’urina di pazienti umani e da cani affetti da cistite.

Patrizia Nebbia, DVM, PhD¹

*

Rosangela Odore, DVM, PhD¹ Clara Tramuta, DVB, PhD¹

Andrea Malabaila, DM² Patrizia Robino, DVM, PhD¹

Gli animali da compagnia sono possibili serbatoi per l’uomo di batteri uropatogeni MDR.

1 Dipartimento di Scienze Veterinarie, Università degli Studi di Torino

2 Laboratorio di Microbiologia, Ospedale degli Infermi, Biella, Italia

* Corresponding author (patrizia.nebbia@unito.it)

Ricevuto: 08/09/2014 - Accettato: 20/11/2014

Lavoro in parte presentato al 42° Congresso Nazionale della Società Italiana di Microbiologia (Torino, 28 settembre – 1° ottobre 2014)

0,&qVWDWRXWLOL]]DWRXQVLVWHPDDXWRPDWL]]DWR0L

FURVFDQ :DONDZD\ V\VWHP 6LHPHQV *HUPDQ\ Ë

VWDWRSUHVRLQFRQVLGHUD]LRQHXQSDQQHOORGLDQWL

ELRWLFLFRPSUHQGHQWHOHFODVVLGLIDUPDFLSLIUHTXHQ

WHPHQWH XWLOL]]DWH LQ WHUDSLD XPDQD H YHWHULQDULD /D

OLVWDGHJOLDQWLELRWLFLqULSRUWDWDLQ7DEHOOD,QEDVH

DOODULVSRVWDDOWHVWGLVHQVLELOLWjJOLLVRODWLVRQRVWDWL

FODVVLÀFDWLFRPHVHQVLELOLRUHVLVWHQWLFDWHJRULDLQFXL

VRQR VWDWL LQFOXVL DQFKH L FHSSL LQWHUPHGL YHUVR FLD

VFXQIDUPDFRWHVWDWR*OLLVRODWLUHVLVWHQWLDGDOPHQR

FODVVLGLDQWLELRWLFLVRQRVWDWLGHÀQLWL0'5LQDFFRUGR

FRQTXDQWRVXJJHULWRUHFHQWHPHQWHGD0DJLRUDNRVHW

al.

.

$QDOLVLVWDWLVWLFD

/H GLIIHUHQ]H FLUFD OD SHUFHQWXDOH GL DQWLELRWLFRUHVL

VWHQ]DIUDFHSSLLVRODWLGDFDQHHXRPRVRQRVWDWHDQD

OL]]DWHPHGLDQWHLOWHVWr

-DYD6WDW,OOLPLWHGLVLJQLÀ

FDWLYLWjqVWDWRÀVVDWRDS

5,68/7$7,

/D )LJXUD  ULDVVXPH LO SURÀOR GL

UHVLVWHQ]DGHLFHSSLGLE. coli isolati GDOFDQHHGDOO·XRPR,QHQWUDPELL

JUXSSLODUHVLVWHQ]DYHUVRODWHWUDFL

FOLQDqULVXOWDWDGHO3HUFHQWXDOL

HOHYDWHGLUHVLVWHQ]DVRQRLQROWUHVWD

WH RVVHUYDWH SHU QRUÁR[DFLQD 

H  ULVSHWWLYDPHQWH QHO FDQH H

QHOO·XRPR SLSHUDFLOOLQD  H

HGDPSLFLOOLQDH,Q

HQWUDPEHOHVSHFLHODUHVLVWHQ]DQHL

FRQIURQWL GHJOL DOWUL DQWLELRWLFL HUD

LQIHULRUHDO/DVHQVLELOLWjYHUVR

IRVIRPLFLQDLPLSHQHPPHURSHPHQ

HQLWURIXUDQWRLQDqULVXOWDWDFRPSUH

VD WUD LO  HG LO  3HU TXDQWR

ULJXDUGD OD FRPSDUD]LRQH GHL GDWL

LQ ULIHULPHQWR DOORULJLQH GHJOL LVR

ODWL FDQH H XRPR L FHSSL RWWHQXWL

GDO FDQH VRQR ULVXOWDWL VLJQLÀFDWLYD

PHQWHSLUHVLVWHQWLULVSHWWRDTXHOOL

XPDQL QHL FRQIURQWL GL FHIDORVSRUL

QH DPR[LFLOOLQDDFLGR FODYXODQLFR H

WREUDPLFLQD S $O FRQWUDULR

O·DPSLFLOOLQDKDPRVWUDWRXQDPLQR

UHDWWLYLWjDQWLEDWWHULFDQHLFRQIURQWL

GHLFHSSLXPDQLULVSHWWRDTXHOOLLVR

ODWLGDOFDQHS

6LDQHLFDQLFKHQHOO·XRPRFLUFDXQWHU]RGHJOLLVROD

WL VRQR ULVXOWDWL 0'5 7XWWDYLD PHQWUH QHOO·XRPR OD

PDJJLRUDQ]D GHJOL LVRODWL  VL q GLPRVWUDWD UHVL

VWHQWHDFODVVLGLDQWLELRWLFLHVRORLODFODVVL

QHOFDQHLOGHLFHSSLqULVXOWDWRUHVLVWHQWHDFODVVL

7DEHOOD

',6&866,21(

,QDQDORJLDFRQTXDQWRRVVHUYDWRLQDOWULSDHVL

LOSUH

VHQWHVWXGLRLQGLFDFKHDQFKHLQ,WDOLDHSLVSHFLÀFD

WDPHQWHLQ3LHPRQWHLOIHQRPHQRGHOO·DQWLELRWLFRUHVL

VWHQ]DqPROWRGLIIXVRWUDLFHSSLGLE. coliXURSDWRJHQL

LVRODWLGDFDQHHXRPR/DSHUFHQWXDOHGLUHVLVWHQ]DDOOH

WHWUDFLFOLQHqLQOLQHDFRQTXDQWRRVVHUYDWRQHOFRUVRGL

SUHFHGHQWLVWXGLFRQGRWWLVLDQHOFDQHFKHQHOO·XRPRHG

qSUREDELOPHQWHLPSXWDELOHDOODSUHVVLRQHIDUPDFROR

JLFDHVHUFLWDWDVXLFHSSLFRPPHQVDOLGLE. coli nel corso GHOWUDWWDPHQWRGLLQIH]LRQLVRVWHQXWHGDDOWULSDWRJH

ni

7DOHFODVVHGLDQWLELRWLFLqVWDWDHGqDWWXDOPHQWH

XWLOL]]DWDLQODUJDPLVXUDVLDLQDPELWRXPDQRFKHYHWH

ULQDULR$QDORJDPHQWHLULVXOWDWLUHODWLYLDGDPSLFLOOLQD

DPR[LFLOOLQDDFLGRFODYXODQLFRHÁXRURFKLQRORQLULÁHW

WRQR VLD SXU FRQ SHUFHQWXDOL OLHYHPHQWH GLIIHUHQWL L

dati presenti in letteratura

5HODWLYDPHQWHDLFHSSLGL

Tabella 1.

Classe chemioantibiotica Principio attivo

Acidi fosfonici Fosfomicina

Aminoglicosidi

Gentamicina Tobramicina Amikacina

Carbapenemici

Ertapenem Imipenem Meropenem

Cefalosporine

Cefuroxime Cefotaxime Ceftazidime Cefepime

Fluorochinoloni

Ciprofloxacina Levofloxacina Norfloxacina

Glicicline Tigeciclina

Inibitori della via metabolica dei folati Trimetoprim-sulfametossazolo

Penicilline Ampicillina

Piperacillina

Penicilline + inibitori delle `-lattamasi Amoxicillina-ac. clavulanico Piperacillina-Tazobactam

Polimixine Colistina

Tetracicline Tetraciclina

Nitrofuranici Nitrofurantoina

Tabella 1. Agenti antimicrobici, suddivisi per classi, utilizzati nelle prove di sensibilità (MIC) su 106 E. coli uropatogeni isolati da cane e da uomo.

Circa il 30% degli isolati sia nel cane che

nell’uomo è risultato MDR: nell’uomo il 7% degli

isolati-MDR era resistente a 7 classi antibiotiche,

nel cane il 37%.

RULJLQHFDQLQDRFFRUUHVRWWROLQHDUHFKHQRQHVLVWRQRDO

PRPHQWRVSHFLDOLWjPHGLFLQDOLDXWRUL]]DWHSHULOFDQH

FRQWHQHQWLLÁXRURFKLQRORQLWHVWDWLQHOFRUVRGHOORVWX

GLRqVWDWDWXWWDYLDGLPRVWUDWDODSRVVLELOLWjGLUHVLVWHQ

]DFURFLDWDWUDLYDULÁXRURFKLQRORQL3HUTXDQWRULJXDU

da E. coliqVWDWDRVVHUYDWDXQDFRUUHOD]LRQHWUDXWLOL]]R

GL HQURÁR[DFLQD H ÁXPHFKLQD H VXFFHVVLYD FRPSDUVD

GLUHVLVWHQ]DQHLFRQIURQWLGHOODFLSURÁR[DFLQD

. Enro

ÁR[DFLQDHFLSURÁR[DFLQDVRQRLQIDWWLVWUXWWXUDOPHQWH

HIXQ]LRQDOPHQWHVLPLOLHODVHFRQGDqLOPHWDEROLWDDW

WLYR GHOOD SULPD

 3HU TXHVWD FDWHJRULD GL FKHPLRDQ

WLELRWLFLqRUPDLGRFXPHQWDWDGDWHPSRO·HVLVWHQ]DGL

XQDFRUUHOD]LRQHWUDIUHTXHQ]DQHOOHSUHVFUL]LRQLHGDX

PHQWRGLFHSSLEDWWHULFLXURSDWRJHQLUHVLVWHQWL

.

$QFKH OD UHVLVWHQ]D DOOH SHQLFLOOLQH VHPLVLQWHWLFKH SXz

WURYDUH JLXVWLÀFD]LRQH QHOO·DPSLD GLVSRQLELOLWj H IUH

TXHQ]DGLSUHVFUL]LRQHVLDLQFDPSRXPDQRFKHYHWHUL

QDULR6HFRQGR:DJQHUHWDO

SHULFHSSL0'5GLE. coli LVRODWLLQFRUVRGL87,QHOFDQHODSHUFHQWXDOHGLUHVLVWHQ

]D DG DPR[LFLOOLQDDFLGR FODYXODQLFR SXz UDJJLXQJHUH

DGGLULWWXUDLO/·HOHYDWDVHQVLELOLWjGHJOLLVRODWLQHL

FRQIURQWLGLIRVIRPLFLQDHQLWURIXUDQWRLQDqLQDFFRUGR

FRQTXDQWRHPHUVRGDVWXGLHSLGHPLRORJLFLULJXDUGDQWL

LOSURÀORGLUHVLVWHQ]DGLE. coliUHVSRQVDELOLGL87,

.

Nel presente studio un WHU]R GHL FHSSL LVRODWL GD

HQWUDPEH OH VSHFLH q ULVXO

WDWR 0'5 5HODWLYDPHQWH

DL FHSSL GL RULJLQH XPDQD

LO GDWR q VRYUDSSRQLELOH D

TXHOOR HPHUVR GDOOR VWXGLR

GL%DUDOHFROODERUDWRUL

se

FRQGRLTXDOLODSHUFHQWXDOH

VLDWWHVWDYDDOFLUFD8Q

ODYRUR UHFHQWH VXO FDQH KD

ULOHYDWR XQD SHUFHQWXDOH GL

E. coli 0'5GHOGRYH

OD PDJJLRU SDUWH GHL FHSSL

ULVXOWDYDHVVHUHUHVLVWHQWHD

EHQ  DQWLELRWLFL FRQ SHU

FHQWXDOLGLUHVLVWHQ]DHOHYD

WHDLEHWDODWWDPLFLHDLÁXR

URFKLQRORQL

 ,O SUREOHPD

GHOOD PXOWLUHVLVWHQ]D WUD L

FHSSLGLRULJLQHFDQLQDqSDUWLFRODUPHQWHHYLGHQWHQHL

VRJJHWWLRVSHGDOL]]DWLHVRWWRSRVWLDWHUDSLDDQWLELRWLFD

. ,QRVWULGDWLQHOFRPSOHVVRFRQIHUPDQRO·HVLJHQ]DGL

XQXWLOL]]RSUXGHQWHHSRQGHUDWRGHLFKHPLRDQWLELRWL

FL,QSDUWLFRODUHGDWDO·HOHYDWDSUHYDOHQ]DQHOFDQHGL

FHSSLUHVLVWHQWLDFODVVLGLFKHPLRDQWLELRWLFLVLVRWWR

OLQHDO·LPSRUWDQ]DGLVHJXLUHXQLWHUGLDJQRVWLFRDSSUR

IRQGLWRHGLULFRUUHUHRYHSRVVLELOHDGLVRODPHQWRGHO

PLFURRUJDQLVPRHWHVWGLVHQVLELOLWjin vitro'DTXHVWR

SXQWRGLYLVWDqLQROWUHSUHIHULELOHGLVSRUUHGHLYDORULGL

0,&GDOPRPHQWRFKHO·HIÀFDFLDin vivoqFRQGL]LRQD

WDGDOOHFRQFHQWUD]LRQLUDJJLXQJLELOLQHOVLWRG·D]LRQH

Nel caso di terapia empirica è importante instaurare il protocollo considerando il trendUHODWLYRDOSURÀORGL

UHVLVWHQ]DGHLSDWRJHQLQHOO·DUHDJHRJUDÀFDLQTXHVWLR

QH$WWXDOPHQWHOHOLQHHJXLGDSHULOWUDWWDPHQWRGHOOH

AK=amikacina;AMX/CL=amoxicillina/ac.clavulanico;AMP=ampicillina;CEF=cefepime;CTX=cefotaxime; CFT=ceftazi dime;CFR=cefuroxime;CIP=ciprofloxacina;CT=colistina;ERT=ertapenem;FOSF=fosfomicina;GM=gentamicina;IMP=

imipenem;LEV=levofloxacina;MEP=meropenem;NT=nitrofurantoina;NORF=norfloxacina;PIP-TZ=piperacillina-tazob actam;PIP=piperacillina;TE=tetraciclina;TIG=tigeciclina;TOB=tobramicina;SXT=trimetoprim-sulfametossazolo

Figura 1. Comparazione dell’antibiotico-resistenza (%) fra E. coli uropatogeni isolati dal cane e dall’uomo (* p<0,05)

Tabella 2

Origine ceppi Resistenza vs

3-4 classi 5-6 classi 7 classi ≥8 classi Totale ceppi

n. isolati % n. isolati % n. isolati % n. isolati n. %

cane 5 26 7 37 7 37 0 19/55 34,5

uomo 22 76 7 24 1 3 0 29/85 35,3

Tabella 2 Distribuzione dei ceppi di E. coli uropatogeni multiresistenti, isolati da cane e da uomo, in classi di chemioantibiotici

Il problema della multiresistenza tra i ceppi di

origine canina è particolarmente evidente nei

soggetti ospedalizzati e sottoposti a terapia

antibiotica e suggerisce l’esigenza di un utilizzo

prudente e ponderato dei chemioantibiotici.

16/5*
$)*"7&

r
E. coli è l’agente causale della maggioranza delle infezioni del tratto urinario (UTI) non complicate sia nell’uomo che negli animali.

r
/FHMJ
VMUJNJ
BOOJ
MF
TFHOBMB[JPOJ
EJ
E. coli multiresistenti, selezionati anche in seguito all’uso eccessivo e all’abuso degli antibiotici, sono in aumento in tutto il mondo.

r
*O
RVFTUP
TUVEJP
TPOP
TUBUJ
QSPWBUJ
in vitro antibiotici ad uso umano e/o veterinario. Circa un terzo dei ceppi di E. coli isolati dall’uomo e altrettanti isolati dal cane risultava multiresistente (MDR).

r
2VFTUJ
SJTVMUBUJ
DPOGFSNBOP
MB
OFDFTTJUÆ
EJ
VO
iter diagnostico accurato ed un protocollo terapeutico mirato. L’uso prudente degli antibiotici in campo umano e veterinario rappresenta una priorità per la salute pubblica sia a livello nazionale che europeo.

87, QHO FDQH UDFFRPDQGDQR FRPH IDUPDFL GL SULPD

VFHOWDDPR[LFLOOLQDDFLGRFODYXODQLFRPJNJ32

7,'RLVXOIDPLGLFLSRWHQ]LDWLPJNJ32%,'

. 7XWWDYLDLULVXOWDWLGHOODQRVWUDULFHUFDLQGLFDQRFKHOH

SHUFHQWXDOLGLUHVLVWHQ]DQHLFRQIURQWLGLTXHVWLIDUPDFL

QRQVRQRWUDVFXUDELOL

$OWULIDUPDFLXWLOL]]DWLQHOFDQHVRQRODQLWURIXUDQWRL

QDHODIRVIRPLFLQD1RQRVWDQWHTXHVW·XOWLPDVLDRUPDL

XWLOL]]DWDDSDUWLUHGDJOLDQQL6HWWDQWDODVHQVLELOLWjGHJOL

LVRODWLGDQRLWHVWDWLFRPSUHVLLFHSSLPXOWLUHVLVWHQWLq

ULVXOWDWDGHFLVDPHQWHHOHYDWDLQDFFRUGRFRQDOWULDXWR

ri

/·HOHYDWDVHQVLELOLWjXQLWDPHQWHDOO·HOHYDWRLQGLFH

WHUDSHXWLFRHDOOHFDUDWWHULVWLFKHFLQHWLFKHQHKDJLXVWL

ÀFDWRO·XWLOL]]RQHOFRUVRGL87,FDQLQHVRVWHQXWHGD

ceppi MDR

ËWXWWDYLDGRYHURVRVRWWROLQHDUHFKHWDOH

WUDWWDPHQWRVLFRQÀJXUDTXDOHXVRLQGHURJDVHFRQGR

O·DUWGHO'HFUHWR/HJLVODWLYRQHSXzSHU

WDQWRHVVHUHDWWXDWRVRORLQYLDHFFH]LRQDOHLQEDVHDG

HIIHWWLYD QHFHVVLWj HR DG LQGLFD]LRQH ODERUDWRULVWLFD

HSUHIHULELOPHQWHLQVHJXLWRDVHJQDOD]LRQHGLYLJLODQ

]D$QFKHODQLWURIXUDQWRLQDSUHVHQWDXQDEXRQDHIÀ

FDFLDQHLFRQIURQWLGLE. coli. Nel caso di ceppi MDR LVRODWLGDFDQHOH0,&

GHOODQLWURIXUDQWRLQD—J

POVRQRULVXOWDWHLQIHULRULDOOHFRQFHQWUD]LRQLRWWHQL

ELOLLQYLYRQHOO·XULQD—JPOLQVHJXLWRDVRP

PLQLVWUD]LRQHSHUYLDRUDOH

7XWWDYLDDQDORJDPHQWHD

TXDQWRDIIHUPDWRSHUODIRVIRPLFLQDDQFKHO·XWLOL]]R

GHOODQLWURIXUDQWRLQDFRPHIDUPDFRGLSULPDVFHOWDQHO

FDQHQRQqLQGLFDWR3LXWWRVWRUDSSUHVHQWDXQDYDOLGD

DOWHUQDWLYDQHOFDVRGLLQIH]LRQLGDEDWWHUL0'5TXDOR

UDODWHUDSLDFRQYHQ]LRQDOHULVXOWLLQHIÀFDFH

,QÀQHVLFRQVLJOLDGLHYLWDUHROLPLWDUHDFDVLHVWUHPLO·X

WLOL]]RGLFDUEDSHQHPLQRQRVWDQWHO·HOHYDWDDWWLYLWjGLPR

strata in vitroQHLFRQIURQWLGLE. coli6LWUDWWDGLIDUPDFL

GLXOWLPDOLQHDLQPHGLFLQDXPDQDXWLOLQHOFDVRGLJUDYL

LQIH]LRQLVRVWHQXWHGDEDWWHUL*UDPQHJDWLYL0'5

.

P UHYDOHQFHRI PXOWLGUXJUHVLVWDQFHLQFDQLQHDQGKXPDQXURSDWKRJHQ(FROLLVRODWHV

6XPPDU\

Treatment of urinary infections caused by E. coli has become increasingly problematic due to the emergence and spread of multidrug-

resistant strains. A retrospective study was carried out to evaluate antibiotic resistance patterns of E. coli isolated from urine samples

of dogs and humans.

%,%/,2*5$),$

 0DDODQG0*XDUGDEDVVL/,QYLWURDQWLPLFURELDODFWLYLW\RI QLWURIX

UDQWRLQDJDLQVW(VFKHULFKLDFROLDQG6WDSK\ORFRFFXVSVHXGLQWHUPHGLXV

LVRODWHGIURPGRJVDQGFDWV9HWHULQDU\0LFURELRORJ\

 7KRPSVRQ 0) /LWVWHU $/ 3ODWHOO -/ et al. &DQLQH EDFWHULDO XULQD

U\ WUDFW LQIHFWLRQV QHZ GHYHORSPHQWV LQ ROG SDWKRJHQV 9HWHULQDU\

-RXUQDO

 %DUDO31HXSDQH60DUDVLQL%3et al.+LJKSUHYDOHQFHRI PXOWLGUXJ

UHVLVWDQFHLQEDFWHULDOXURSDWKRJHQVIURP.DWKPDQGX1HSDO%0&

5HVHDUFK1RWHV

 +HUVKEHUJHU(2SUHD6)'RQDEHGLDQ60et al.(SLGHPLRORJ\RI DQ

WLPLFURELDOUHVLVWDQFHLQHQWHURFRFFLRI DQLPDO RULJLQ$QWLPLFURELDO

&KHPRWKHUDS\

 3LWRXW-'([WUDLQWHVWLQDOSDWKRJHQLF(VFKHULFKLDFROLDQXSGDWHRQ

DQWLPLFURELDO UHVLVWDQFH ODERUDWRU\ GLDJQRVLV DQG WUHDWPHQW ([SHUW

5HYLHZRI $QWL,QIHFWLYH7KHUDS\

 *XDUGDEDVVL / 6FKZDU] 6 /OR\G '+ 3HW DQLPDOV DV UHVHUYRLUV RI  DQWLPLFURELDOUHVLVWDQWEDFWHULD-RXUQDO$QWLPLFURELDO&KHPRWKHUDS\



 %DOO.55XELQ-(&KLULQR7UHMR0et al.$QWLPLFURELDOUHVLVWDQFHDQG

SUHYDOHQFHRI FDQLQHXURSDWKRJHQVDWWKH:HVWHUQ&ROOHJHRI 9HWH

ULQDU\ 0HGLFLQH 9HWHULQDU\ 7HDFKLQJ +RVSLWDO  &DQDGLDQ

9HWHULQDU\-RXUQDO

 2VVLSUDQGL0&&DWWDELDQL)'H5LVLR/et al.$QWLELRWLFUHVLVWDQFHLQ

EDFWHULDLVRODWHGIURPXULQDU\WUDFWVRI FDWVDQGGRJVZLWKQHXURORJLF

LPSDLUPHQW,JLHQH0RGHUQD

 3DSLQL5(EDQL99&HUUL'et al.6XUYH\RQEDFWHULDOLVRODWHVIURP

GRJVZLWKXULQDU\WUDFWLQIHFWLRQVDQGWKHLULQYLWURVHQVLWLYLW\5HYXH

GH0HGLFLQH9HWHULQDLUH

 1HEELD37UDPXWD&2GRUH5et al.*HQHWLFDQGSKHQRW\SLFFKDUDFWH

ULVDWLRQ RI  (VFKHULFKLD FROL SURGXFLQJ FHIRWD[LPDVHW\SH H[WHQGHG

spectrum `ODFWDPDVHVÀUVWHYLGHQFHRI WKH67FORQHLQFDWVZLWK

XULQDU\ LQIHFWLRQV LQ ,WDO\ -RXUQDO RI  )HOLQH 0HGLFLQH DQG 6XUJHU\

>(SXEDKHDGRI SULQW@

 7UDPXWD&5RELQR31XFHUD'et al.0ROHFXODUFKDUDFWHUL]DWLRQDQG

DQWLPLFURELDOUHVLVWDQFHRI IDHFDODQGXULQDU\(VFKHULFKLDFROLLVRODWHG

IURPGRJVDQGKXPDQVLQ,WDO\9HWHULQDULD,WDOLDQD

 0DJLRUDNRV $3 6ULQLYDVDQ $ &DUH\ 5% et al. 0XOWLGUXJUHVLVWDQW

H[WHQVLYHO\GUXJUHVLVWDQWDQGSDQGUXJUHVLVWDQWEDFWHULDDQLQWHUQD

WLRQDO H[SHUW SURSRVDO IRU LQWHULP VWDQGDUG GHÀQLWLRQV IRU DFTXLUHG

UHVLVWDQFH&OLQLFDO0LFURELRORJ\DQG,QIHFWLRQ

 :DJQHU6*DOO\'/$UJ\OH6$0XOWLGUXJUHVLVWDQW(VFKHULFKLDFROL

IURPFDQLQHXULQDU\WUDFWLQIHFWLRQVWHQGWRKDYHFRPPHQVDOSK\ORW

\SHVORZHUSUHYDOHQFHRI YLUXOHQFHGHWHUPLQDQWVDQGDPS&UHSOLFRQV

9HWHULQDU\0LFURELRORJ\

 .DUDPL11RZURX]LDQ)$GOHUEHUWK,et al.7HWUDF\FOLQHUHVLVWDQFH

LQ(VFKHULFKLDFROLDQGSHUVLVWHQFHLQWKHLQIDQWLOHFRORQLFPLFURELRWD

$QWLPLFURELDO$JHQWV$QG&KHPRWKHUDS\

 *LEVRQ-6&REEROG517URWW'-&KDUDFWHUL]DWLRQRI PXOWLGUXJUHVL

VWDQW(VFKHULFKLDFROLLVRODWHGIURPH[WUDLQWHVWLQDOFOLQLFDOLQIHFWLRQVLQ

DQLPDOV-RXUQDORI 0HGLFDO0LFURELRORJ\

 0RQLUL5'DVWHKJROL.)OXRURTXLQRORQHUHVLVWDQWEscherichia coli iso

ODWHGIURPKHDOWK\EURLOHUVZLWKSUHYLRXVH[SRVXUHWRÁXRURTXLQROR

QHV,VWKHUHDOLQN"0LFURELDO(FRORJ\LQ+HDOWKDQG'LVHDVH



 .QJ.5LRQG-/:DQQHU03KDUPDFRNLQHWLFVRI HQURÁR[DFLQDQG

LWVPHWDEROLWHFLSURÁR[DFLQDIWHULQWUDYHQRXVDQGRUDODGPLQLVWUDWLRQ

RI  HQURÁR[DFLQ LQ GRJV -RXUQDO RI  9HWHULQDU\ 3KDUPDFRORJ\ $QG

7KHUDSHXWLFV

 *RHWWVFK:YDQ3HOW:1DJHONHUNH1et al.,QFUHDVLQJUHVLVWDQFHWRÁXR

URTXLQRORQHVLQHVFKHULFKLDFROLIURPXULQDU\WUDFWLQIHFWLRQVLQWKHQH

WKHUODQGV-RXUQDORI $QWLPLFURELDO&KHPRWKHUDS\

 1LFNHO-&8ULQDU\7UDFW,QIHFWLRQVDQG5HVLVWDQW%DFWHULD5HYLHZVLQ

XURORJ\²

 $ERGHULQ2$$EGX$52GHWR\LQ%:et al.$QWLPLFURELDOUHVLVWDQFH

LQ(VFKHULFKLDFROLVWUDLQVIURPXULQDU\WUDFWLQIHFWLRQV-RXUQDORI WKH

1DWLRQDO0HGLFDO$VVRFLDWLRQ

 6KDKHHQ %: %RRWKH '0 2\DU]DEDO 2$ et al. $QWLPLFURELDO UHVL

VWDQFHSURÀOHVDQGFORQDOUHODWHGQHVVRI FDQLQHDQGIHOLQH(VFKHULFKLD

FROL SDWKRJHQV H[SUHVVLQJ PXOWLGUXJ UHVLVWDQFH LQ WKH 8QLWHG 6WDWHV

-RXUQDORI 9HWHULQDU\,QWHUQDO0HGLFLQH

 1DP+0/HH+6%\XQ-:et al.3UHYDOHQFHRI DQWLPLFURELDOUHVLVWDQ

FHLQIHFDO(VFKHULFKLDFROLLVRODWHVIURPVWUD\SHWGRJVDQGKRVSLWDOL

]HGSHWGRJVLQ.RUHD0LFURELDO'UXJ5HVLVWDQFH

 :HHVH-6%ORQGHDX-0%RRWKH'et al.$QWLPLFURELDO8VH*XLGHOLQHV

IRU7UHDWPHQWRI 8ULQDU\7UDFW'LVHDVHLQ'RJVDQG&DWV$QWLPLFURELDO

*XLGHOLQHV:RUNLQJ*URXSRI WKH,QWHUQDWLRQDO6RFLHW\IRU&RPSDQLRQ

$QLPDO,QIHFWLRXV'LVHDVHV9HWHULQDU\0HGLFLQH,QWHUQDWLRQDO



 )DODJDV 0( .DVWRULV $& .DSDVNHOLV $0 et al. )RVIRP\FLQ IRU WKH

WUHDWPHQWRI  PXOWLGUXJUHVLVWDQWLQFOXGLQJH[WHQGHGVSHFWUXPEHWD

ODFWDPDVH SURGXFLQJ (QWHUREDFWHULDFHDH LQIHFWLRQV D V\VWHPDWLF UH

YLHZ/DQFHW,QIHFWLRXV'LVHDVHV

 +XEND 3 %RRWKH '0 ,Q YLWUR VXVFHSWLELOLW\ RI  FDQLQH DQG IHOLQH

(VFKHULFKLDFROLWRIRVIRP\FLQ9HWHULQDU\0LFURELRORJ\